Introduction

Injectable therapy options include:1–3
- basal insulin plus a glucagon-like peptide-1 (GLP-1) receptor agonist:
  - IDeg, insulin degludec; IDegLira, an FRC of insulin degludec and the GLP-1 RA liraglutide; iGlarLixi, an FRC of insulin glargine 100 U/mL and the GLP-1 RA lixisenatide; FRC, fixed-ratio combination; GLP-1 RA, glucagon-like peptide-1 receptor agonist:

Research summary

1. National Institute for Clinical Excellence (NICE). Available from https://www.nice.org.uk/guidance/ng28/resources/ Diabetes Care.
2. Davies et al. 2018;41:2669–2701 Diabetes Care.
3. Kaneko et al. 2015;107:139–47 Diabetes Obes Metab.
4. Liebl et al. Diabetes Res Clin Pract.
5. McCrimmon R et al. Diabetes Obes Metab. 2014;2:885–93
diabetes research.
6. Kaneko et al. Diabetes Ther. 2020;22: 2179–88
diabetes research.
7. Liebl et al. Diabetes Res Clin Pract.
8. McCrimmon R et al. Diabetes Obes Metab. 2014;2:885–93
diabetes research.
9. Jude et al. Diabetes Obes Metab.
10. Taneda et al. Diabetes Care.
11. Jude et al. Diabetes Obes Metab.
12. Khunti et al. Diabetes Obes Metab.
13. Satoh et al. Diabetes Ther.
14. Nauck et al. 2011;7:193 –5 PLoS One.
15. Aroda et al. Diabetes Care.
16. Rosenstock et al. 2016;39:2026–35 Diabetes Care.
17. Buse et al. 2019. Diabetes Care.
18. Gough et al. Diabetes Ther.
19. Linjawi et al. Diabetes Ther.
20. Rayner et al. Diabetes Care.
21. Rayner et al. Diabetes Care.
22. Aroda et al. Diabetes Obes Metab.
23. Davies et al.

Conclusion

Titratable fixed-ratio combination of basal insulin plus a glucagon-like peptide 1 receptor agonist: A novel, simplified alternative to premix insulin for type 2 diabetes